- Home
- NVA vs ADAG Comparison
NVA vs ADAG Comparison
Compare NVA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- ADAG
- Stock Information
- Founded
- NVA 1987
- ADAG 2011
- Country
- NVA Australia
- ADAG China
- Employees
- NVA N/A
- ADAG N/A
- Industry
- NVA
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- NVA
- ADAG Health Care
- Exchange
- NVA NYSE
- ADAG Nasdaq
- Market Cap
- NVA 69.7M
- ADAG 81.9M
- IPO Year
- NVA N/A
- ADAG 2021
- Fundamental
- Price
- NVA $12.87
- ADAG $1.42
- Analyst Decision
- NVA
- ADAG Strong Buy
- Analyst Count
- NVA 0
- ADAG 1
- Target Price
- NVA N/A
- ADAG $8.00
- AVG Volume (30 Days)
- NVA 18.8K
- ADAG 29.9K
- Earning Date
- NVA 01-01-0001
- ADAG 03-24-2025
- Dividend Yield
- NVA N/A
- ADAG N/A
- EPS Growth
- NVA N/A
- ADAG N/A
- EPS
- NVA N/A
- ADAG N/A
- Revenue
- NVA N/A
- ADAG $103,204.00
- Revenue This Year
- NVA N/A
- ADAG $6,488.89
- Revenue Next Year
- NVA N/A
- ADAG $57.50
- P/E Ratio
- NVA N/A
- ADAG N/A
- Revenue Growth
- NVA N/A
- ADAG N/A
- 52 Week Low
- NVA $4.35
- ADAG $1.33
- 52 Week High
- NVA $19.00
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- ADAG 39.32
- Support Level
- NVA N/A
- ADAG $1.36
- Resistance Level
- NVA N/A
- ADAG $1.92
- Average True Range (ATR)
- NVA 0.00
- ADAG 0.13
- MACD
- NVA 0.00
- ADAG -0.00
- Stochastic Oscillator
- NVA 0.00
- ADAG 13.79
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.